| Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) NCT04509700 | Fase 2 | En marcha, sin reclutar |
| Linfoma de células del manto NCT04849715 | Fase 3 | Retirado antes de empezar |
| To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302) NCT04796922 | Fase 3 | Retirado antes de empezar |
| Linfoma NCT03235544 | Fase 2 | Completado |
| Mielofibrosis NCT04551053 | Fase 3 | Interrumpido |
| Mielofibrosis NCT04551066 | Fase 3 | Interrumpido |
| Linfoma NCT04434937 | Fase 2 | Completado |
| Tumores malignos avanzados NCT04831996 | Fase 1 | Completado |
| Linfoma de células B NCT03424122 | Fase 1 | Completado |
| Tumores malignos avanzados NCT04831944 | Fase 1 | Completado |
| A Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia NCT03538041 | Fase 2 | Completado |
| A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101) NCT02018861 | Fase 1/2 | Completado |
| Linfoma NCT03039114 | Fase 1 | Completado |
| Linfoma NCT03126019 | Fase 2 | Completado |
| A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis NCT02718300 | Fase 2 | Interrumpido |
| Linfoma NCT03144674 | Fase 2 | Completado |
| A Study of the Safety and Tolerability of INCB050465 in Pemphigus Vulgaris NCT03780166 | Fase 2 | Retirado antes de empezar |
| Linfoma NCT03314922 | Fase 1 | Completado |
| A Study of INCB050465 in Primary Sjögren's Syndrome NCT03627065 | Fase 2 | Completado |
| Linfoma NCT02998476 | Fase 2 | Completado |